mayoly spindler

What mayoly spindler does

Mayoly Spindler is a French, family-owned and independent pharmaceutical laboratory founded in 1909, specializing in gastroenterology and dermocosmetics. The group operates across five business units — Consumer Healthcare (OTC), Pharma (prescription), Dermocosmetics, Diagnostic, and Production — with a portfolio of heritage brands including Smecta (clay-based gastrointestinal therapy), Meteospasmyl, Probiolog (probiotics), Topicrem (sensitive-skin skincare), BeauTerra (natural cosmetics), Kersiens (micronutrition), and Colchicine.

The company manufactures in five GMP-certified production facilities, four of which are in France (Rueil-Malmaison HQ, Dammarie-les-Lys, L'Isle-sur-la-Sorgue, Dreux, Auxerre), with proprietary expertise in natural clay transformation for Smecta's active ingredient and in probiotic and dietary supplement formulation. Certifications span ISO 22716, GxP, 21 CFR Part 11, and GAMP 5.

Mayoly generates revenue through prescription and OTC pharmaceutical sales, consumer health products, dermocosmetics, in-vitro diagnostics, and third-party contract manufacturing. Distribution is primarily B2B through pharmacy channels — a French field sales force (Délégués Pharmaceutiques) covering independent pharmacies and chains, supplemented by wholesalers and a network of subsidiaries and exclusive distributors in more than 100 countries. Roughly 65% of revenue is international. Disclosed revenue exceeded €500 million in 2022 following the integration of Ipsen's Family Health business and the acquisition of Pharm Nature, with a publicly stated target of over €600 million by 2027. Headcount stands at approximately 2,200 globally.

Name

mayoly spindler

Legal name

MAYOLY

Website

https://mayoly.com

Company type

Private

Founded year

1909

Operating status

Operating

Short description

Mayoly Spindler is a French, family-owned independent pharmaceutical laboratory founded in 1909, specializing in gastroenterology and dermocosmetics, and serving patients and consumers through pharmacy channels in over 100 countries with brands such as Smecta, Meteospasmyl, Topicrem, and Probiolog.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Gastroenterology pharmaceuticals
• Dermocosmetic skincare
• Consumer healthcare products
• Probiotic supplements
• Pharmaceutical manufacturing

Headquarters

HQ city

Chatou

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical products (Rx & OTC): Prescription and over-the-counter pharmaceutical products primarily in gastroenterology, including gastrointestinal medicines such as Meteospasmyl and colchicine-based treatments. Revenue from direct sales to pharmacies and hospital procurement.
2. Consumer Healthcare / OTC: Consumer health products sold over-the-counter in pharmacies, including digestive health supplements, dermocosmetics, and nutritional supplements under brands such as Probiolog, Topicrem, and BeauTerra.
3. Contract Manufacturing / Production: Manufacturing services for third-party pharmaceutical and health products through Mayoly's network of 5 GMP-certified production facilities in France, serving both the group's own portfolio and external clients.
4. Diagnostic products: In-vitro diagnostic products distributed internationally through export channels and partnerships.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Mayoly Spindler is a French family-owned pharmaceutical laboratory that develops, manufactures, and markets prescription and over-the-counter drugs, probiotics, dermocosmetic skincare, and in-vitro diagnostics, with core specialization in gastroenterology and dermocosmetics. The company sells products such as Meteospasmyl, Smecta, Probiolog, Colchicine, and Topicrem under established brands across 100+ countries, operating five GMP-certified manufacturing facilities (four in France).

Product overview

Mayoly Spindler is a French, family-owned, independent pharmaceutical laboratory with over 100 years of expertise. The company operates across five business units: Consumer HealthCare (OTC products), Pharma (prescription medications), Dermocosmetics (skincare brands including Topicrem and BeauTerra), Diagnostic (in vitro diagnostics), and Production (manufacturing with 5 factories in France). Key products include Meteospasmyl (gastrointestinal), Probiolog (probiotics), Smecta (clay-based therapy), Colchicine (strategic medication), and Kersiens (micronutrition). The company generated over 500M€ revenue in 2022 with 65% international sales across more than 100 countries, targeting 600M€ by 2027.

Differentiator

Problem solved

Functional benefit

Brands

• BeauTerra: Natural and sensory cosmetics brand, manufactured in France, sold in pharmacies. Positioned among leaders in hygiene products in pharmacies with strong growth dynamics.
• Kersiëns
• Topicrem
• Probiolog
• Smecta

Products and services

• Meteospasmyl Prescription gastrointestinal medication for digestive disorders, bloating, and intestinal discomfort, supplied to pharmacies and hospitals.
• Smecta Clay-based therapeutic medication (using natural argile thérapeutique) for gastrointestinal disorders, manufactured at the L'Isle-sur-la-Sorgue GMP site.
• Colchicine Strategic essential medication produced domestically in partnership with GALIEN for patients requiring colchicine treatment.
• Probiolog Probiotic supplement range covering adult, child, and infant indications for gastrointestinal health and gut microbiota balance, sold in pharmacies.
• Topicrem Dermo-cosmetic skincare brand developed for sensitive skin and dermatological conditions, sold in pharmacies to consumers and recommended by healthcare professionals.
• BeauTerra Natural and sensory cosmetics brand manufactured in France and sold in pharmacies, positioned among leaders in pharmacy hygiene products.
• Kersiens

Quantifiable outcome

• Revenue exceeded €500M in 2022 following Ipsen CHC acquisition
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• GALIENcoreStrategic or Co-development Partner · 1 June 2026MAYOLY and GALIEN partnered to relocate colchicine pharmaceutical production to Auxerre, France, strengthening French pharmaceutical sovereignty. This strategic partnership involves domestic production of a strategically essential medication for patients.
• Pierre-Louis Attwell / IMOCA RESILIENTcoreGTM or Marketing Partner · 1 June 2026MAYOLY partnered with skipper Pierre-Louis Attwell and his IMOCA RESILIENT yacht for the Vendée Globe 2028, Mayoly's first participation in the legendary ocean race. The partnership, engaged since 2016, reflects shared values of entrepreneurship, ambition, authenticity, and challenge. The RESILIENT name symbolizes the ability to transform obstacles into momentum.
• IpsencoreStrategic or Co-development Partner · 1 July 2022MAYOLY acquired Ipsen's Family Health (Santé Familiale) business in July 2022, significantly expanding its consumer health portfolio. This major acquisition contributed to revenue exceeding €500M in 2022 and strengthened Mayoly's position in the French consumer health market.
• Pharm NaturecoreStrategic or Co-development Partner · 1 June 2022MAYOLY acquired Pharm Nature in June 2022, finalizing the acquisition in September 2022. This acquisition strengthened Mayoly's position in the dietary supplement (compléments alimentaires) market, complementing its existing probiotic (Probiolog) portfolio.
• AzurRx BiopharmaminorStrategic or Co-development Partner · 1 January 2019MAYOLY restructured its R&D partnership with US-based AzurRx Biopharma (NASDAQ:AZRX) in April 2019 regarding the MS1819 project. The restructuring modified the terms of collaboration on this gastrointestinal drug development program.
• afa Crohn RCHminorGTM or Marketing Partner · 1 January 2019MAYOLY supported the 'Vogue avec un Crohn' project in partnership with afa Crohn RCH (patient association), raising awareness about Crohn's disease. The initiative included sailing challenges and public engagement campaigns supported by Mayoly Spindler and MSD France.
• Hôpital Necker-Enfants malades AP-HPminorGTM or Marketing Partner · 1 January 2019Topicrem, Mayoly's dermocosmetic brand, has been committed for over a year to Hôpital Necker-Enfants malades AP-HP through the therapeutic well-being space 'Les Miroirs Complices', supporting children and adolescents with dermatological conditions through psychological, psychomotor, socio-aesthetic, and sophrology workshops.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Bouchara-Recordati: French subsidiary of Recordati specializing in pharma and consumer health products distributed via French pharmacy networks. Comparable in product mix and pharmacy-channel GTM.
• Faes Farma: Spanish pharma and consumer health company with OTC and prescription GI/skin products distributed through pharmacy channels. Closely comparable mid-cap European specialty pharma + consumer health model.
• Laboratoires Urgo: French family-owned healthcare company active in wound care, dermocosmetics, and consumer health sold through pharmacy channels. Closely comparable in ownership structure, French base, and pharmacy-led GTM motion.
• Galderma: Global pure-play dermatology and dermocosmetics company. Directly comparable on the dermocosmetics and sensitive-skin therapeutic skincare side of Mayoly's portfolio, particularly the Topicrem brand franchise.
• Stada Arzneimittel: European mid-cap specialty pharma and consumer health company with strong OTC and generics presence across European pharmacy channels. Comparable to Mayoly in scale (~€3–4B revenue), pharmacy-led GTM, and diversified pharma/consumer health mix.
• Pierre Fabre: French family-owned pharmaceutical and dermo-cosmetic laboratory with a similar portfolio split between prescription pharma, OTC consumer health, and pharmacy-channel dermocosmetics — a structural twin to Mayoly's five-business-unit model.
• Ipsen: French specialty pharmaceutical company historically focused on gastroenterology and consumer health. Direct peer given shared French base, GI franchise overlap (Mayoly acquired Ipsen's Family Health business in 2022), and similar specialty-pharma positioning.

Broad incumbents

• Perrigo: Global consumer self-care company (OTC, skincare, digestive health) with strong European pharmacy presence. Comparable across consumer health categories and OTC distribution model, though operating at significantly larger scale.
• Bayer Consumer Health: Division of Bayer focused on OTC and consumer health including digestive health (e.g., Iberogast). A broad incumbent competing with Mayoly in European pharmacy channels for GI and women's health OTC.
• Sanofi (Consumer Healthcare): Global pharmaceutical incumbent with a sizable Consumer Healthcare business including digestive health and dermocosmetics brands. Overlaps with Mayoly across OTC GI and pharmacy skincare but at materially greater scale and with broader geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/mayoly
• YouTubeyoutube.com/channel/mayoly
• Facebookfacebook.com/Mayoly
• LinkedInlinkedin.com/company/mayoly
• Instagraminstagram.com/mayoly

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about mayoly spindler